Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Anebulo Pharmaceuticals, Inc. (ANEB : NSDQ)
 
 • Company Description   
Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.18 Daily Weekly Monthly
20 Day Moving Average: 4,477 shares
Shares Outstanding: 23.34 (millions)
Market Capitalization: $74.24 (millions)
Beta:
52 Week High: $9.33
52 Week Low: $2.95
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -26.05% -19.02%
12 Week -54.57% -48.94%
Year To Date -48.29% -36.83%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1415 RANCH ROAD 629 SOUTH SUITE 201
-
LAKEWAY,TX 78734
USA
ph: 737-203-5270
fax: -
ir@anebulo.com http://www.anebulo.com
 
 • General Corporate Information   
Officers
Daniel Schneeberger - Chief Executive Officer
Joseph F. Lawler - Chairman
Rex Merchant - Chief Financial Officer
Aron R. English - Director
Jason Aryeh - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 034569103
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 09/28/22
Share - Related Items
Shares Outstanding: 23.34
Most Recent Split Date: (:1)
Beta:
Market Capitalization: $74.24 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 09/28/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.33
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 88.41%
vs. Previous Quarter: -60.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -36.12
12/31/21 - -28.23
09/30/21 - -35.76
ROA
03/31/22 - -35.66
12/31/21 - -27.82
09/30/21 - -35.04
Current Ratio
03/31/22 - 201.08
12/31/21 - 379.70
09/30/21 - 33.72
Quick Ratio
03/31/22 - 201.08
12/31/21 - 379.71
09/30/21 - 33.72
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.74
12/31/21 - 0.81
09/30/21 - 0.85
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©